SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

Faldaprevir is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor which, when administered for 24 weeks in combination with pegylated interferon α-2a and ribavirin (PegIFN/RBV) in treatment-naive patients in a prior study (SILEN-C1; M. S. Sulkowski et al., Hepatology 57:2143–2154,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dieterich, Douglas, Asselah, Tarik, Guyader, Dominique, Berg, Thomas, Schuchmann, Marcus, Mauss, Stefan, Ratziu, Vlad, Ferenci, Peter, Larrey, Dominique, Maieron, Andreas, Stern, Jerry O., Ozan, Melek, Datsenko, Yakov, Böcher, Wulf Otto, Steinmann, Gerhard
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4068493/
https://ncbi.nlm.nih.gov/pubmed/24709256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02497-13
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados